GlaxoSmithKline is considering cutting prescription-linked commissions for its sales staff and reducing drug prices in China amid fallout from a growing corruption probe.
Executives at the UK-based pharmaceutical group are exploring ways to apply changes to its commercial model that have already been adopted in other countries, including the UK and the US, where it has overhauled its operations in response to past accusations of aggressive marketing.
The moves are still under debate and unlikely to be finalised while it focuses on negotiations with the Chinese authorities over allegations that at least four of its top executives in the country were involved in bribery and tax manipulation over six years.
您已阅读28%（711字），剩余72%（1822字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。